Loading patent…
AssigneeOklahoma Medical Research Foundation
InventorsKenji Fukudome, Charles T. Esmon
Estimating the term…
Human protein C and activated protein C were shown to bind to endothelium specifically, selectively and saturably (Kd=30 nM, 7000 sites per cell) in a Ca2+ dependent fashion. Expression cloning revealed a 1.3 kb cDNA that coded for a novel type I transmembrane glycoprotein capable of binding protein C. This protein appears to be a member of the CD1/MHC superfamily. Like thrombomodulin, the receptor involved in protein C activation, the endothelial cell protein C receptor (EPCR) function and message are both down regulated by exposure of endothelium to TNF. Identification of EPCR as a member of the CD1/MHC superfamily provides insights into the role of protein C in regulating the inflammatory response, and determination of methods for pharmaceutical use in manipulating the inflammatory response.
A method for enhancing an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor comprising administering to a patient in need of treatment thereof an antibody or antibody fragment immunoreactive with said endothelial cell protein C/activated protein C receptor in an amount sufficient to block binding of protein C or activated protein C to the receptor by binding to the endothelial cell protein C/activated protein C receptor.
Dependencies are inferred from the claim text.